Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Konjac Mannan and Ginseng Compositions and Methods and Uses Thereof

a technology of mannan and ginseng and compositions, applied in the field of konjac mannan and ginseng compositions and methods, can solve the problem of no clear effective composition or method for reducing blood glucos

Inactive Publication Date: 2008-06-05
VUKSAN HLDG
View PDF30 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The konjac-mannan and ginseng compositions effectively lower blood glucose, improve insulin sensitivity, and modulate lipid profiles, blood pressure, and cholesterol levels, enhancing conventional treatment outcomes for diabetes and coronary heart disease.

Problems solved by technology

Whether soluble fibre is able to reduce a cluster of risk factors is speculative.
However, to date, there is no clearly effective composition or method for reducing blood glucose.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Konjac Mannan and Ginseng Compositions and Methods and Uses Thereof
  • Konjac Mannan and Ginseng Compositions and Methods and Uses Thereof
  • Konjac Mannan and Ginseng Compositions and Methods and Uses Thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0090]All participants followed the experimental protocol with little difficulty. According to three-day food records collected over the baseline and washout periods, subjects ate their usual low-fat (27 g per day) diets (Table 3). In addition, during the treatment periods, returned food and biscuits from metabolic diets indicated that subjects consumed an average of 93% and 95% of diet calories prescribed on the KJM+ and control (WB) treatments respectively and 88% (137 g / day) KJM+ test and 91% (142 g / day) WB placebo biscuits. Consumption patterns translated into an insignificant decrease in body weight during both treatment periods (Table 4). There was no correlation between changes in weight and serum lipids, glucose or blood pressure (data not shown). The only side effect experienced was a transient complaint of flatulence and soft stools reported by 37% and 24% of participants during the KJM+ and the control (WB) treatments respectively, but none refused to continue the study.

example 2

[0091]Blood lipids were improved during KJM+ treatment compared to control (Table 4). The primary lipid endpoint, total / HDL cholesterol, decreased significantly by 5.7±2.3% (P=0.034, α=0.05) during the KJM+ treatment compared to an insignificant increase of 4.7±4.4% (P=0.316, α=0.017) on control. The resultant between-treatment decrease of 10±4.0% on the KJM+ treatment was significant (P=0.028, α=0.05). The secondary endpoints of total and LDL cholesterol also fell significantly by 16±2.7% (P=0.001, α=0.005), 25±3.9% (P=0.001, α=0.005), during KJM+ treatment compared to 4.9±3.7% (P=0.20, α=0.006), and 4.8±5.9% (P=0.45, α=0.008) on control. Resultant between-treatment differences of 11±4.2% (P=0.025, α=0.005) and 19±6.8% (P=0.033, α=0.006), were insignificant, however, after correction by the Bonferroni-Hochberg procedure. The combined fall in total cholesterol and LDL on the KJM+ treatment indicated reclassification of the lipid status of 6 of the 11 subjects from elevated to normal...

example 3

[0094]Improvements in glycemic control were observed on the KJM+ treatment compared to control (Table 4). The primary glycemic endpoint, serum fructosamine, was reduced insignificantly during both the KJM+ and control treatments by 6.1±2.4% (P=0.03, α=0.025), and 0.5±1.4% (P=0.751, α=0.05) respectively, after correction by the Bonferroni procedure. The resultant between treatment decrease of 5.7±1.7% on KJM+ was nevertheless significant (P=0.007, α=0.017). No significant differences between treatment regimes were seen for the secondary endpoints of insulin or glucose, although during the KJM+ treatment, fasting glycemia fell significantly by 11±3.0% (P=0.004, α=0.008) compared to 1.5±6.1% (=−0.804, α=0.013) on control.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Described are a number of compositions, namely a konjac mannan mixture, a ginseng composition, and a composition comprising konjac mannan and American ginseng. Methods of use of these compositions are described including their use for reducing blood glucose in non-diabetic and diabetic individuals, as well as reducing postprandial blood glucose in such individuals. Applications in the treatment of hyperlipidemia, high blood pressure, an increase in nitric oxide, Syndrome X and cardiovascular disease are also described. Various other applications of the compositions and methods are also described.

Description

FIELD OF THE INVENTION[0001]The invention relates to compositions comprising Konjac-Mannan, Ginseng or both and methods of use and uses of these compositions, such as in lowering blood glucose including post-prandial and long-term effects. In one aspect this invention is in the field of glucose and other heart disease risk factors management. In one aspect the invention is concerned with dietary approaches to such management. In another aspect it is concerned with compositions and methods of reducing blood glucose, specificallyBACKGROUND OF THE INVENTION[0002]Abnormal glucose tolerance and insulin resistance are related to multiple cardiovascular risk factors especially reduced HDL, elevated serum triglycerides and hypertension (Liese et al. (1998)). When clustered these abnormalities increase the risk of coronary heart disease (CHD) morbidity and mortality, an effect that is independent of other conventional risk factors (Trevisan et al. (1998)). Co-ocurrence is usually present in ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K36/25A61P3/10A21D2/18A21D2/36A23L1/30A23L19/10A61K36/258A61K36/48A61K36/888
CPCA21D2/18A21D2/36A61K36/888A61K36/48A61K36/258A61K36/25A23V2002/00A23L1/3002A23L1/2147A61K2300/00A23V2250/5066A23V2250/2124A23L19/115A23L33/105A61P3/10
Inventor VLADIMIR, VUKSAN
Owner VUKSAN HLDG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com